Table 2.

Screening and treatment of chronic renal patients colonized with S. areus on peritoneal dialysis

Author	Year	Design	Pacient (n.)		NCSA (n./%)		Treatment		Follow up		Erradication	ESI		Peritonitis
			Treated group	Control group	Treated group	Control group	Treated group	Control group	Treated group	Control group		Treated group	Control group	Treated group	Control group
Mupirocin Study Group [16]	1996	DCR	134	133	18	24	Nasal mupirocin 2x/day for 5 days every 4 weeks	Placebo	18 months	18 months	90 %	14	44	18	24
Wong [17]	2003	ECR	73	81	16	14	CESS mupirocin 1x/d	No treatment	5 months	5 months	NT	0	10	1	1
Zimmerman [18]	1991	ECR	32	32	9	8	Oral rifampicin 300 mg 2x/d for 5d every 3 months	No treatment	10 months	12 months	NT	3	12	3	5
Lye [19]	1994	ECR	41	105	3	6	Cefazolin + CESS gentamicin	No treatment	36 months	36 months	NT	2	4	2	0
Sesso [20]	1998	ECR	9	13	5	5	Nasal and CESS sodium fusidate	No treatment	7,8 months	7,8 months	43 %	3	5	1	6
Sesso [20]	1998	ECR		13	5	5	Oral Ofloxacin (dd)	No treatment	7,8 months	7,8 months	40 %	2	5	4	6
Bernardini [21]	2005	ECR	67	66	9	9	CESS mupirocin 2x/d for 5d every 3 months	CESS gentamicin 2x/d for 5d every 3 months	8 months	8 months	97 %	0	10	1	1
Fontán [22]	1993	ECR	12	10	12	10	Nasal mupirocina for 7 d	Nasal neomicin for 7 d	9,5 months	9,5 months	100 %	1	1	0	1
Bernardini [23]	1996	ECR	41	41	18	18	CESS mupirocin daily	Oral Rifampicin 600 mg 1x/d for 5d every 3 months	months	12 months	NT	5	6	2	1
Cavdar [24]	2004	ECR	18	18	3	0	CESS mupirocin 3x/week	CESS mupirocin 1x/week	6 months	6 months	83 %	0	1	0	1

Note: n number of patients, % Percentage, NCSA nasal carrier of S. aureus, CESS catheter exit site skin, DBRCT Double blind randomized controlled trial, RCT randomized clinical trial, NT not tested, ESI Catheter Exit Site Infection, 3x/w three times per week